Liquid Biopsies That Can Screen and Detect Cancer Early Winning Over Investors
ROCKVILLE, Md., March 28, 2017 /PRNewswire-USNewswire/ -- Interest is high in the development of blood-based tests that can be used to screen individuals for cancer. That isn't new, liquid biopsy industry has attracted attention and investment for the past few years. What is changing is that investors are more interested in screening and early detection ? not just monitoring. Healthcare research firm Kalorama Information made the finding in a recent report. Kalorama Information's World Market for Molecular Diagnostics report provides markets for CTC (circulating tumor cell) testing, a type of testing related to liquid biopsy. Cell-free DNA is another type of market and Kalorama has also covered that market in detail.
At the beginning of March, it was widely reported that Grail had raised $900 million of a planned $1 billion, in the first close of a Series B financing round Investors in this second round are reported to include Arch Venture Partners (leading the round), Amazon, Bristol-Myers Squibb, Celgene, Johnson and Johnson Innovation, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. Other developments include:
In January 2017, Illumina had announced that GRAIL planned to raise over $1 billion in a Series B financing round. Illumina was an early investor in GRAIL. Only one year earlier, Illumina announced that GRAIL had been formed to enable cancer screening from a simple blood test, and that GRAIL was initially funded by over $100 million in Series A financing.
Freenome is also focusing on early detection of cancer. At the beginning of March, Freenome announced that it had raised $65 million in a Series A financing round. This financing was led by Andreessen Horowitz.
Other investors included GV (Google Ventures), Polaris Partners, Charles River Ventures, Eric Schmidt's Innovation Endeavors, Spectrum 28, Asset Management Ventures.
There were other investors from previous rounds such as Data Collective and Founders Fund. The previous year (in June 2016), Freenome announced that the company had raised $5.55 million in a seed round that was also led by Andreessen Horowitz.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
The condition commonly known as "fatty liver" is serious and can have significant health consequences if not properly addressed. But with the right approach, doctors say it may be possible to control and even reverse some of its effects....
Watercrest Senior Living Group proudly announces Larissa Kostal as Executive Director of the award-winning Watercrest Myrtle Beach Assisted Living and Memory Care community....
The YMCA of Metropolitan Chicago announces the appointment of Alicia Gonzalez as its Chief Sports Impact Officer. This appointment builds on the organization's rich history as a leader in sports and legacy of inspiring change through the Power of...
Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation...
Donaldson Company, Inc. , a leading worldwide provider of innovative filtration products and solutions, announced its Isolere Bio (Isolere) and Univercells Technologies businesses are developing an integrated upstream and downstream platform for...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA. The newly built 154,000-square-foot lab and...